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Abstract
Important progress has been made in recent years in the development and clinical use of drugs for the treatment of human immunode-
ﬁciency virus type 1 (HIV-1) infection. Nevertheless, when antiretroviral therapy fails to be fully suppressive, new viral variants emerge,
thus allowing HIV-1 to escape from drug pressure by accumulating mutations. Between 50% and 70% of treated patients with virological
rebound harbour some form of drug-resistant virus; transmitted drug resistance in drug-naı¨ve populations has reached 5–20% in areas
of the world with access to treatment. The emergence of drug-resistant viruses remains the limiting factor in HIV-1 management, being
a major cause of treatment failure, and being associated with clinical progression and death. All international guidelines focus on the
importance of tailoring antiretroviral therapy to the individual patient, on the basis onf HIV-1 genetic data, integrated with clinical, labo-
ratory and therapeutic information. The aim of this review is to provide useful information to clinicians and virologists about how and
when to use genotypic resistance testing in clinical practice, especially in the management of the ﬁrst stages of HIV-1 patient care and
treatment decisions.
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Introduction
From the 1980s, stunning advances in antiretroviral therapy
have been made; human immunodeﬁciency virus type 1 (HIV-
1)-infected patients are today experiencing increased longev-
ity, reduced HIV-1-related complications, and improved quality
of life. However, severe adverse effects, therapy adherence
and the evolution of drug-resistant viruses are frequently
compromising virological and clinical outcomes.
Today, the main aim of treatment is to achieve maximum
and durable suppression of viral replication (HIV-1 viral load,
<50 copies/mL), with a combination of antiretroviral agents
to which the virus is susceptible [1–3]. Failure to achieve this
result leads to the emergence of drug-resistant variants,
which are signiﬁcantly associated with poorer survival and
increased risk of death [4,5]. Monitoring of drug resistance is
thus of the utmost importance and, in the developed world,
resistance testing is now a standard of care in HIV-1
infection management. All guidelines recommend appropriate
use of these tests, with the aim of helping clinicians in setting
up a correct and individualized therapeutic strategy. How-
ever, the widespread distribution of HIV-1 infection in differ-
ent areas, with different economic and social settings,
generates difﬁculties in deﬁning optimized screening and
treatment protocols, in terms of ﬁnite budgets, expertise
and time constraints. The aim of this review is to provide
useful information to clinicians and virologists regarding
how and when to use genotypic resistance testing in clinical
practice, especially in patients starting their ﬁrst therapeutic
regimen.
Use of Resistance Assays in Clinical Practice
The goal of resistance testing is to identify, in clinical sam-
ples, viral variants harbouring mutations causing or contribut-
ing to drug resistance, and thus to provide information to
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assist in the selection of active antiretroviral regimen(s) that
are more likely to achieve and to maintain viral suppression.
Genotypic resistance testing is generally preferred because
of the faster turn-around time, lower cost, and enhanced
sensitivity in detecting mixtures of wild-type and resistant
viruses. The test is based on traditional population (Sanger)
sequencing, and is able to detect quasi-species representing,
on average, at least 20% of a viral population. However, for
patients with a complex treatment history, results derived
from both genotypic resistance tests (GRTs) and phenotypic
resistance tests might provide critical and complementary
information to guide regimen changes [1]. Once the viral
gene target sequence has been obtained, several interpreta-
tion algorithms are freely available with which to analyse the
resistance for all approved nucleoside reverse transcriptase
inhibitors (NRTIs), non-nucleoside reverse transcriptase
inhibitors (NNRTIs), protease inhibitors (PIs) and integrase
inhibitors (INIs): the ANRS (National AIDS Research
Agency) drug resistance interpretation algorithm (http://
www.hivfrenchresistance.org/), the HIVdb drug resistance
interpretation algorithm (http://hivdb.stanford.edu/), or the
Rega Institute Drug-Resistance Interpretation Algorithm
(http://www.rega.kuleuven.be).
Fig. 1 shows an example of a ‘real-life’ working routine in a
virology centre. The histograms represent the number of
GRTs performed in the last 10 years in our laboratory, the
largest reference centre in Rome, and its surrounding
area for HIV-1. Not surprisingly, and in line with the
increased efﬁcacy of antiviral regimens, the number of GRTs
of patients treated with highly active antiretroviral therapy
(HAART) has decreased in recent years (>600 performed in
2009 vs. ‡1000 in 2004–2006), although the number is now
stable, conﬁrming that failures continue to occur in clinical
practice. Following guideline recommendations, a steady
increase in GRTs requested for drug-naive patients was also
observed, starting from 2004 (with >600 being performed in
2009).
Use of GRTs in Drug-naı¨ve Patients
HIV-1 is an extremely variable and highly evolving pathogen.
One of the main consequences of its unique nature is that
the selection of the ﬁrst therapeutic regimen is crucial for
the success of subsequent therapies, thus limiting the use of
drugs against which the virus has already selected primary
mutations. Transmission of drug-resistant HIV-1 strains is a
well-documented phenomenon, and most studies agree that
transmitted drug resistance (TDR) is associated with a higher
risk of virological failure of ﬁrst-line antiretroviral therapy
[6,7], a higher risk of developing resistance even to those
drugs in their regimen that were originally fully active [8],
and faster progression to advanced disease [9].
In AIDS Clinical Trials Group A5095, it has been shown
that baseline NNRTI resistance can more than double the
risk of virological failure in response to an initial NNRTI-con-
taining regimen (hazard ratio 2.27 (95% CI 1.15–4.49);
p 0.018) [7]. Interestingly, one study from the CASCADE
collaboration reported a steeper CD4+ cell count decline in
subjects with primary resistance than in those without [9].
All over the world, TDR has been analysed in recent years.
The risk of a transmitted virus being resistant to at least one
antiretroviral drug has a remarkable difference in prevalence
(2.2–24%), even in different areas of the same country. The
major part of the variation is related to differences in access to
therapy (universal vs. limited), with a range of 5–18% in the
USA and Europe (Tables 1 and 2), 13.8% in Asia, and 2.2–24%
in Africa (Sungkanuparph et al., 12th European AIDS Confer-
ence, 2009, Abstract 3.1/3; Kasang et al., 12th European AIDS
Conference, 2009, Abstract 3.1/9; Kim et al., 17th Conference
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FIG. 1. Histograms representing the number of genotypic resistance
tests (GRTs) performed in our virology laboratory in Rome in the
last 10 years. (a) Number of pol (protease (PR)/reverse transcriptase
(RT)) GRTs performed over the years. (b) Number of GRTs of PR/
RT, GP41, integrase and V3-Gp120 performed over the years. The
numbers given at the top of the ‘overall’ bar indicate the total
number of GRTs per year.
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on Retroviruses and Opportunistic Infection, 2010, Abstract
580; Prejean et al., 17th Conference on Retroviruses and
Opportunistic Infection, 2010, Abstract 581; Lee et al., 17th
Conference on Retroviruses and Opportunistic Infection,
2010, Abstract 582 [10,11]). Conﬂicting data regarding trends
in the frequency of transmitted variants over time have also
been reported, with some studies showing a stable TDR over
time [12], some showing a decline (Poon et al., 17th Confer-
ence on Retroviruses and Opportunistic Infection, 2010,
Abstract 583 [11]), and some showing an increase [13]. All
together, these results indicate that differences in patient pop-
ulations (in terms of risk behaviour, adherence and ethnicity)
and in the types of antiretroviral regimen used can compro-
mise data interpretation. Therefore, only local studies can pro-
vide a correct determination of the prevalence of resistance in
drug-naı¨ve patients in that particular setting, avoiding errone-
ous conclusions with relevant clinical consequences.
Although previous models assumed that TDR reﬂects direct
infection from treated individuals, the dynamics of transmis-
sion of drug-resistant HIV-1 strains are still unclear. Recently,
through phylogenetic analysis of >10 000 HIV-1 pol gene
sequences generated in the UK from both treatment-naı¨ve
and treatment-experienced individuals, Hue` et al. identiﬁed
ﬁve treatment-independent viral clusters, generated in the late
1990s, but containing mutations conferring cross-resistance to
antiretroviral drugs [14]. Phylogenetic analysis indicated that
these reservoirs have persisted in the HIV-1-infected popula-
tion for up to 8 years. The existence of sustained reservoirs of
resistance in the absence of treatment has the capacity to
threaten the long-term efﬁcacy of antiretroviral therapy, and
suggests that there is a limit to the decline of TDR. Given the
current decrease in resistance transmitted from treated indi-
viduals, a greater proportion of resistance is likely to come
from drug-naı¨ve lineages. These ﬁndings provide new clues to
help in the development and management of treatment pro-
grammes in resource-rich and developing countries.
To date, all current guidelines recommend HIV-1 drug
resistance testing for all HIV-1-infected individuals entering
into clinical care, regardless of whether therapy will be
initiated immediately or deferred. In addition, genotypic resis-
tance testing is recommended for all pregnant women prior
to therapy initiation and for those entering pregnancy with
detectable HIV-1 RNA levels while on therapy [1,2,15,16].
Health economic studies have shown that in antiretroviral-
naı¨ve persons, baseline genotypic resistance testing is a cost-
effective intervention when the prevalence of TDR exceeds
5% [17], and currently involves genotypic resistance testing
for mutations in the reverse transcriptase and protease
genes. However, as pre-existing genotypic and phenotypic ral-
tegravir resistance is completely absent or extremely rare in
INI-naı¨ve patients, integrase genotyping in all patients before
raltegravir treatment may not be cost-effective and should
not be recommended at this point. Future evidence of TDR
to INIs, and/or more detailed knowledge of the clinical rele-
vance of integrase minor variants and/or polymorphisms, may
lead experts to reconsider this option [18].
TABLE 1. Prevalence of primary human immunodeﬁciency virus type 1 (HIV-1) drug resistance by drug class, from 2003 to
2008, in different parts of the world
2003 2004 2005 2006 2007 2008
Patients (N)a 58 54 43 29 40 42
Any resistance (%) 10 11 19 17 28 10
NRTI (%) 7 6 12 7 15 7
NNRTI (%) 2 6 9 10 8 5
PI (%) 9 4 0 7 8 0
NNTRI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
aPatients enrolled in the Options Project, a longitudinal cohort study in San Francisco of acute/early HIV infection (<12 months) (Jain et al., 16th Conference on Retroviruses
and Opportunistic Infection, 2009, Abstract P673).
TABLE 2. Prevalence of primary human immunodeﬁciency virus type 1 (HIV-1) drug resistance by drug class, from 2002 to
2008, in different parts of the world
2002–2004 2005 2006–2007 2008
Patients (N)a 464 326 550 –
Any resistance (%) 16 14 14 –
NRTI (%) 14 10 8 –
NNRTI (%) 8 5 6 –
PI (%) 6 4 2 –
NNTRI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
aThe genotypic resistance tests were performed at each site on plasma samples collected before the initiation of antiretroviral therapy, and the FASTA sequences were
uploaded to the Italian ARCA database [11].
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In the absence of therapy, TDR mutations may revert to
the wild type, although in a highly variable proportion of
patients, and at discrete time-points. The M184V/I mutations
revert more often and more rapidly than thymidine analogue
mutations, T215 revertants, NNRTI mutations, or PI muta-
tions (Jain et al., 16th Conference on Retroviruses and
Opportunistic Infection, 2009, Abstract P672). This is proba-
bly attributable to reduced viral ﬁtness of M184V/I variants,
and a lower likelihood of being ‘ﬁxed’ by compensatory
mutations. When TDR is being analysed, reversion events
need to be considered. This underlines the importance of
performing resistance testing on patients as soon as they
enter into clinical care, minimizing the chance that a resis-
tance mutation will become undetectable.
Repeating a GRT just before treatment initiation should
be considered for all patients. This is because of the chance
of a superinfection with a drug-resistant virus during the
time between entry into clinical care and initiation of anti-
retroviral therapy, especially for patients with high-risk
behaviour. Recently, it has been shown that superinfection
events can be detected in approximately 10% of HAART-
naı¨ve men who have sex with men, with a sudden increase
in viral load during routine follow-up (Doyle et al., 8th Euro-
pean HIV Drug Resistance Workshop, 2010, Abstract 89). In
addition, for patients with TDR, it is important to re-analyse
the degree of resistance at the time of treatment initiation,
together with historical GRTs, in order to assess the best
ﬁrst-line treatment, considering also archived mutations.
The presence of at least one surveillance drug resistance
mutation [19] in a drug-naı¨ve patient may suggest the pres-
ence of hidden minor species with other drug resistance
mutations. Indeed, it is important to remember that resistant
viruses may decline over time to below the detection limit
of standard genotypic resistance testing, but still persist as
minority species, and can be stored in pro-viral DNA of
infected cells.
These minority species may become dominant during
treatment, increasing the probability of virological failure of
the ﬁrst-line regimen [20,21]. Underestimating the burden of
resistance in drug-naı¨ve individuals can affect optimal antiret-
roviral therapy selection, especially for patients diagnosed
long after becoming infected, when primary resistance muta-
tions may have decayed [22,23].
In practice, some studies have shown that detection of
pre-existing minority NNRTI-resistant variants in drug-naı¨ve
subjects increases by more than three-fold the risk of
virological failure of ﬁrst-line NNRTI-based regimens [24],
especially with adequate treatment adherence [25,26]. On the
other hand, some studies have not conﬁrmed these ﬁndings,
suggesting that this area requires further investigation [27–29].
Use of Genotypic Resistance Testing in
Patients with First Virological Failure
Drug resistance acquired during suboptimal antiretroviral
therapy is much more common than TDR. The prevalence
of drug resistance in therapy-exposed subjects was estimated
to be 39–53% in 2006 [8,30], with the prevalence of triple-
drug-resistant virus being 5%. Fortunately, the degree of
resistance has declined in recent years, thanks to the intro-
duction of newer potent agents, improvements in effective
drug combination, and, last but not least, a better under-
standing of HIV-1 drug resistance. In a systematic overview
of 20 clinical trials that comprised 7970 adult patients recei-
ving ﬁrst-line HAART, which consisted of dual NRTIs
combined with a third agent (either an NNRTI or a ritona-
vir-boosted PI), initial therapy with ritonavir-boosted PI regi-
mens resulted in less resistance within and across drug
classes. In this meta-analysis, virological failure rates at
week 48 were comparable, but the incidence of M184V and
K65R mutations in reverse transcriptase, as well as resis-
tance to the third agent, were higher for subjects starting
NNRTI-based HAART (Table 3) [31].
Moreover, from the ‘real world’ of medical practice, in a
recent analysis of 7891 patients who started recommended
treatments in the UK, using NRTIs plus either a ritonavir-
boosted PI or an NNRTI, virological failure by 8 years was
relatively common (28%), and was paralleled by an apprecia-
ble risk of resistance detection, although the detection rate
TABLE 3. Pooled resistance data at week 48 of virological failure of ﬁrst-line highly active antiretroviral therapy
Regimen
No. of
patients
No. (%) of
patients
with VF
No. of patients
with available
genotype data
(% of those with VF)
No. of patients (% of genotype analysis group)
No major
resistance
Major NNRTI or
PI mutation
M184V/I
mutations
Any
TAM K65R
Ritonavir-boosted PI 3063 216 (7.1) 180 (83) 123 (56.9) 7 (3.2) 44 (20.4) 2 (1.0) 0
NNRTI 4212 240 (7.6) 291 (80) 114 (38.0) 149 (52.0) 106 (36.4) 7 (3.0) 17 (8.3)
Modiﬁed from Gupta et al. [31].
NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; TAM, thymidine analogue mutation; VF, viral failure.
1514 Clinical Microbiology and Infection, Volume 16 Number 10, October 2010 CMI
ª2010 The Authors
Clinical Microbiology and Infection ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 1511–1517
for class-speciﬁc resistance was lower for those who started
a ritonavir-boosted PI-based regimen. The cumulative proba-
bilities of detecting any mutation, one or more major NRTI
International AIDS Society-USA (IAS-USA) mutations, one or
more major NNRTI IAS-USA mutations (in those starting an
NNRTI) and one or more major PI IAS-USA mutations (in
those starting a PI) were 17%, 14%, 15% and 7%, respec-
tively, by 8 years [32,33]).
Current guidelines state that the goal of therapy is to
achieve and maintain HIV-1 RNA below detectable levels, with
recommendations to switch regimens upon virological failure,
because of the adverse consequences of higher levels of vira-
emia. Virus continues to evolve if kept under pressure by failing
antiviral therapy. Maintenance of unchanged antiviral therapy in
subjects with virological failure leads to further resistance
accumulation, an increase in cross-resistance, and decreased
chances of efﬁcacy of subsequent drugs and regimens. In an
analysis of 106 chronically HIV-1-infected patients on a stable
antiretroviral regimen for at least 120 days, with plasma HIV-1
RNA levels >1000 copies/mL and at least one genotypic resis-
tance mutation, the risk of losing one fully suppressive drug or
two partly suppressive drugs was estimated to be 32% at
1 year [34]. The risk of developing a new major protease
mutation was 17%, and the risk of developing a new nucleo-
side-associated mutation at 1 year was 23%. Similarly, a EuroS-
IDA study based on 110 HIV-1-infected patients with plasma
HIV-1 RNA levels >400 copies/mL found that, in patients kept
on the same virologically failing HAART regimen for a median
time of 6 months, there was a considerable accumulation of
drug resistance mutations, particularly in patients with an initial
low level of resistance to the failing regimen [35]. Recently, it
was also observed that maintaining a failing ﬁrst NNRTI regi-
men for 6–12 months was the only factor associated with the
development of full resistance to etravirine (‡4 etravirine
Tibotec score [36]) (Zaccarelli et al., 9th International Con-
gress on Drug Therapy in HIV Infection 2008, Abstract
PO179). This suggests that quick withdrawal of a failing NNRTI
regimen, possibly during the ﬁrst 3 months, can maintain etra-
virine sensitivity, thus preserving a treatment option.
Therefore, in the framework of correct therapeutic
sequencing, clinicians must prevent resistance accumulation
by detecting virological failure early, and by quickly switching
HAART to fully suppressive combinations. Guidelines recom-
mend the performance of HIV-1 genotypic resistance testing
when managing suboptimal viral load reduction, and to assist
in the selection of active drugs when changing antiretroviral
regimens in patients with virological failure and HIV-1 RNA
levels >1000 copies/mL [1,2]. In persons with >500 but
<1000 copies/mL, testing may be unsuccessful, but should
still be considered. Genotypic resistance testing in the setting
of virological failure should be performed while the patient is
taking prescribed antiretroviral drugs, or, if this is not possi-
ble, within 4 weeks after discontinuing therapy [1].
The recent suggestion to perform genotypic resistance
testing also at levels <1000 copies/mL reﬂects the wide vari-
ability of skill in performing resistance testing among different
laboratories. In real life, many reports have shown the highly
successful use of genotypic resistance testing in HIV-1-
infected patients with detectable viraemia between 50 and
1000 copies/mL [37–39]. In addition, multiple drug resistance
mutations can also be selected and detected at HIV-1
rebound with low viral loads [37,40]. Indeed, resistance
mutations have been found to accumulate in 68–93% of
patients with persistent viraemia between 50 and 1000
copies/mL [41]. Therefore, in patients with a suboptimal
response, resistance testing at week 4 is recommended.
Genotype validity with plasma HIV-1 RNA level <75
copies/mL was also conﬁrmed in 49 of 50 patients with a
previous or follow-up genotype [42]. Overall, the belief that
genotypic resistance testing is unreliable in samples with low-
level viraemia should be reassessed.
Fig. 2 shows another example of a virology working routine.
The histograms represent the number of GRTs performed at
the ﬁrst failure, according to viral load and year of treatment
start. Interestingly, the percentage of GRTs with viral loads
<1000 copies/mL has increased greatly in the last 2 years. This
reﬂects the new perception that genotypic resistance testing
also provides excellent information regarding the degree and
type of resistance in situations of low viraemia.
Conclusions
The importance of resistance testing in clinical practice has
been widely recognized and acknowledged in guidelines,
60
2008–2010 (N = 22) Before 2008 (N = 400)
50
40
30
G
R
Ts
 a
t f
ir
st
 fa
ilu
re
 (%
)
20
10
0
<1000 1000–10 000 >10 000
Viral load (copies/mL)
FIG. 2. Number of genotypic resistance tests (GRTs) performed at
ﬁrst treatment failure in relation to viral load and year of treatment
start.
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although its implementation in clinical practice needs reas-
sessment. The long-term clinical implications of resistance in
today’s situation of multiple drug availability require further
cohort studies. At the same time, the use of resistance test-
ing before therapy initiation gives the chance of the best
selection of antivirals to be used in the ﬁrst regimen. The
technical feasibility of resistance testing at ﬁrst failures with
low viraemia (a quite common situation) seems to be far
greater than what is suggested by guidelines. Its implementa-
tion is relevant in preventing the further evolution of the
virus and the selection of mutations causing multiple cross-
resistance, which limits therapeutic options.
Advances in ultrasensitive technologies now allow the
detection of resistant variants present at very low levels
(<0.1%) in the quasi-species populations of infected patients.
However, appropriate validation and standardization of such
new technologies, together with signiﬁcant cost reductions
and assessment of the clinical relevance of minor variants, is
mandatory before approval of their future use in diagnostic
routine.
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